Get Involved
Australian & New Zealand Childrens Haematology/Oncology Group

Clinical Trials

Hypermutant Cancers Trial: A Pilot Study of Nivolumab in Paediatric Patients with Hypermutant Cancers

Hypermutant Cancers

Status: In Development

A hypermutant cancer means there are many mutations which prevents the body from fixing the mutations as they form inside tumour or bone marrow or blood. Every child that takes part in this trial will first have their cancer sample analysed to confirm they have a hypermutant cancer and/or proof of a replication repair deficiency.

In adults, a drug named nivolumab has shown to work well in hypermutant cancers and we would like to test to see if this is also true for children.  Nivolumab is a humanized monoclonal antibody (a type of protein that is normally made by the immune system to help defend the body from infection and cancer), which is used in the treatment of other adult cancers, such as skin, lung and kidney tumours. Patients will be treated with nivolumab and we will monitor their cancer to see how it responds to the treatment.

Disease Stage: Relapsed/refractory

Patient Age Range: 1- <25 years old

Sample Size: Up to 50 patients

Recruitment Period: 4 years

Trial Sponsors:

  • International: The Hospital for Sick Children, Toronto
  • National: ANZCHOG

Read more at the Clinical Trial Registry

ANZCHOG acknowledges the valuable support of the Hypermutant Cancers Trial by Cure Brain Cancer Foundation

logo-cure-brain-cancer.jpg